FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
- Status
- RECRUITING
- Phase
- PHASE3
Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
- Status
- RECRUITING
- Phase
- PHASE2
Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
- Status
- RECRUITING
- Phase
- PHASE3
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
- Status
- SUSPENDED
- Phase
- PHASE1
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
- Status
- RECRUITING
- Phase
- PHASE3
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)
- Status
- RECRUITING
- Phase
- PHASE2
HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER
- Status
- COMPLETED
- Phase
- N/A
ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu
- Status
- NOT_YET_RECRUITING
- Phase
- EARLY_PHASE1
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2